Zelnorm was a steady seller for Novartis before cardiovascular red flags led to the irritable bowel syndrome (IBS) med’s collapse. Now—more than a decade after its recall and with new owners—Zelnorm's ...
An investment in promotional strategy has helped fuel new prescription growth for Novartis brands Diovan and Zelnorm, chief marketing officer Kurt Graves said yesterday during UBS’ Global Life ...
Novartis said Friday it has pulled its irritable bowel treatment Zelnorm (tegaserod maleate) off the US market after new clinical data showed an increased risk of cardiovascular events in patients ...
US WorldMeds announced that the Food and Drug Administration (FDA) has approved the reintroduction of Zelnorm (tegaserod) for the treatment of irritable bowel syndrome with constipation (IBS-C) in ...
Novartis pulled bowel drug Zelnorm from U.S. shelves on Friday at the request of regulators because clinical trial data indicated a possible link to heart attacks and strokes. The move is a body blow ...
Novartis ' Zelnorm, approved by U.S. regulators in July, could well reach annual sales of $1 billion or more. But in order for that to happen, Novartis has to convince gun-shy doctors that the drug is ...
The U.S. Food and Drug Administration has asked Novartis to stop selling its chronic constipation drug Zelnorm after combining 29 clinical studies turned up an increased cardiovascular risk. The ...
March 30, 2007 (East Hanover, NJ) - Novartis, in compliance with an FDA request, has suspended marketing and sales of its irritable bowel/constipation drug Zelnorm (tegaserod maleate), after an ...
EAST HANOVER, N.J., March 30 (UPI) -- The U.S. Food and Drug Administration has asked Swiss firm Novartis to suspend sales of its bowel drug Zelnorm, the company said Friday. The decision came after ...
Novartis cut its 2007 sales forecast on Friday after pulling bowel drug Zelnorm from U.S. shelves at the request of regulators because clinical trial data indicated a possible link to heart attacks ...
April 29, 2004 — The U.S. Food and Drug Administration (FDA) and Novartis notified healthcare professionals on April 26 of revisions to the warnings and precautions sections of labeling for tegaserod ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results